Prozkoumejte nejčtenější články a videa na Campus Sanofi
Niemann-Pick: Comprendre le déficit en sphingomyélinase acide en 4 minutes
The Bright study demonstrated similar efficacy and safety of Toujeo® (Glargine 300) compared to degludec (insulin degludec) in type 2 diabetes patients who had not previously received basal insulin1.
The Bright study demonstrated similar efficacy and safety of Toujeo® (Glargine 300 U/ml) compared to degludec 100 U/ml in type 2 diabetes patients who had not previously received basal insulin1.
May 17–21, 2025; San Francisco, California, US